Valeant Pharmaceuticals International VRX
The three reasons
- 1
Traditional P/E ignores Valeant's 'Platform Value' from disciplined M&A capital allocation
- 2
Valeant earned >20% unlevered IRR on $20bn+ of acquisitions since 2008 (e.g., B&L $8.7bn -> $21bn+)
- 3
Stock worth $330+/share vs. ~$223 today, before any large transformative deal or pipeline credit
Primary demands
- Investors should value Valeant using a 'Platform Value' framework that credits future value-enhancing acquisitions, not just current earnings multiples
- Re-rate Valeant at ~16x forward earnings reflecting durable business (20x) and patent cliff (8x) blended
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Notable slides (8)
Notes
Long thesis (defense/promotion) of an existing portfolio holding, not a contrarian short. Frames Valeant alongside other 'platform' companies (Jarden, PAH, Nomad, Danaher, AB InBev, TransDigm) as a misunderstood acquirer whose value comes from disciplined capital allocation. Standard Pershing Square production: blue/green color blocks, simple title-and-bullet layouts, annotated share-price charts, modest data viz. The B&L 'before/after Valeant ownership' value-creation table (p.20) and the 2020 EPS scenario grid (p.28) are the analytic centerpieces. Sum-of-parts splits the business into 'Durable' (~70% earnings, 20x multiple) and 'Patent Cliff' (~30%, 8x DCF). No villain or attacker tone -- this is educational/analytical. Famously aged badly: Valeant collapsed in late 2015 after Citron's short report and Philidor pricing scandal, and Pershing exited at multi-billion-dollar loss in 2017.